ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd., often referred to as IPA, is a leading biotechnology company headquartered in Canada. Founded in 2010, the company has established itself as a key player in the field of antibody discovery and development, with significant operations across North America and Europe. Specialising in custom monoclonal antibodies, ImmunoPrecise offers a unique suite of services, including hybridoma development and phage display technologies, which set them apart in the competitive landscape. The company has achieved notable milestones, such as the successful launch of its proprietary antibody discovery platform, enhancing its market position. With a commitment to innovation and quality, ImmunoPrecise Antibodies Ltd. continues to support the biopharmaceutical industry, providing essential tools for research and therapeutic development.
DitchCarbon Score
How does ImmunoPrecise Antibodies Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ImmunoPrecise Antibodies Ltd.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
ImmunoPrecise Antibodies Ltd.'s reported carbon emissions
ImmunoPrecise Antibodies Ltd., headquartered in Canada, currently does not have any publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the absence of specific data, it is unclear how ImmunoPrecise Antibodies Ltd. is addressing climate change or contributing to sustainability efforts within the biotechnology sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ImmunoPrecise Antibodies Ltd. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
